Poly(ethylene oxide)-Poly(propylene oxide)-based copolymers for transdermal drug delivery: An overview

Tropical Journal of Pharmaceutical Research

Volumn 11, Issue 5, 2012, Pages 855-866

  Yapar, Evren Algin ^a   Inal, Özge ^b  

^a MINISTRY OF HEALTH   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Drug delivery; Hydrogel; PEO PPO based copolymer; Poloxamer; Transdermal

Indexed keywords

ARGIPRESSIN; CAPSAICIN DERIVATIVE; COPOLYMER; INSULIN; LIDOCAINE; MACROGOL; NAPROXEN; PIROXICAM; POLOXAMER; PROPRANOLOL; PROPYLENE OXIDE; TIMOLOL; TOLFENAMIC ACID;

ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; LIPOPHILICITY; MICELLIZATION; MOLECULAR INTERACTION; NONHUMAN; SUSTAINED DRUG RELEASE; THERMAL ANALYSIS;

EID: 84868036178     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm 2007; 66: 303-317.
2. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
3. Lipinski C. Poor aqueous solubility-an industry wide problem in drug delivery. Am Pharm Rev 2002; 5: 82-85.
4. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Del Rev 2001; 47: 113-131.
5. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Design 2006; 12: 4669-4684.
6. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine, TIBTECH 2000; 18: 412-420.
7. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Exp Opin Drug Del 2006; 3: 139-162.
8. Cafaggi S, Russo E, Caviglioli G, Parodi B, Stefani R, Sillo G, Leardi R, Bignardi G. Poloxamer 407 as a solubilising agent for tolfenamic acid and as a base for a gel formulation. Eur J Pharm Sci 2008; 35:19-29.
9. Cafaggi S, Leardi R, Parodi B, Caviglioli G, Bignardi G. An example of application of a mixture design with constraints to a pharmaceutical formulation. Chemom Intell Lab Syst 2003; 65: 139-147.
10. Suh H, Jun HW. Physicochemical and release studies of naproxen in poloxamer gels. Int J Pharm 1996; 129: 13-20.
11. Shin SC, Cho CW, Oh IJ. Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats. Int J Pharm 2000; 193: 213-218.
12. Ye F, Yaghmur A, Jensen H, Larsen SW, Larsen C, Østergaard J. Real-time UV imaging of drug diffusion and release from Pluronic F127 hydrogels. Eur J Pharm Sci 2011; 43: 236-243.
13. Choi JS, Shin SC. Preparation and Evaluation of Pranoprofen Gel for Percutaneous Administration. Drug Dev Ind Pharm 2007; 33: 19-26.
14. Gonzales N, Sumano H. Design of two liquid Ibuprofen-Poloxamer-Limonene or Menthol preparations for dermal administration, Drug Delivery 2007; 14: 287-293.
15. Shin SC, Cho CW, Oh IJ. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. Int J Pharm 2001; 222: 199-203.
16. Escobar-Chavez JJ, Quintanar-Guerrero D, Ganem-Quintanar A. In Vivo Skin Permeation of Sodium Naproxen Formulated in Pluronic F-127 Gels: Effect of Azone and Transcutol. Drug Dev Ind Pharm 2005; 31:447-454.
17. El-Kattan AF, Asbill CS, Kim N, Michniak BB. Effect of Formulation Variables on the Percutaneous Permeation of Ketoprofen from Gel Formulations. Drug Delivery 2000; 7: 147-153.
18. Lee BJ, Lee TS, Cha BJ, Kim SH, Kim WB. Percutaneous absorption and histopathology of a poloxamer-based formulation of capsaicin analog. Int J Pharm 1997; 159: 105-114.
19. Ur-Rehman T, Tavelin S, Gröbner G. Effect of DMSO on micellization, gelation and drug release profile of Poloxamer 407. Int J Pharm 2010; 394: 92-98.
20. Liaw J, Lin YC. Evaluation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) gels as a release vehicle for percutaneous fentanyl. J Control Release 2000; 68: 273-282.
21. Shin SC, Cho CW, Yang KH. Development of lidocaine gels for enhanced local anesthetic action. Int J Pharm 2004; 287: 73-78.
22. Pandit NK, Wang D. Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels. Int J Pharm 1998; 167: 183-189.
23. Suedee R, Bodhibukkana C, Tangthong N, Amnuaikit C, Kaewnopparat S, Srichana T. Development of a reservoir-type transdermal enantioselective-controlled delivery system for racemic propranolol using a molecularly imprinted polymer composite membrane. J Control Release 2008; 129: 170-178.
24. Stamatialis DF, Rolevink HHM, Koops GH. Transdermal timolol delivery from a Pluronic gel. J Control Release 2006; 116(2): 53-5. doi:10.1016/j.jconrel.2006.09.046
25. Nair V, Panchagnula R. Poloxamer gel as vehicle for transdermal iontophoretic delivery of arginine vasopressin: evaluation of in vivo performance in rats. Pharmacol Res 2003; 47: 555-562.
26. Pillai O, Panchagnula R. Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J Control Release 2003; 89: 127-140.
27. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23(12): 2709-28. doi: 10.1007/s11095-006-9104-4.
28. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82(2-3): 189-212.
29. Kabanov AV, Lemieux P, Vinogradov S, Alakhov V. Pluronic block copolymers: novel functional molecules for gene therapy. Adv Drug Del Rev 2002; 54: 223-233.
30. Ruel-Gariépy E, Leroux JC. In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm 2004; 58: 409-426.
31. Rassing J, Attwood D. Ultrasonic velocity and lightscattering studies on the polyoxyethylenepolyoxypropylene copolymer Pluronic F127 in aqueous solution. Int J Pharm 1983; 13: 47-55.
32. Zhou Z, Chu B. Anomalous association behavior of an ethylene oxide/propylene oxide ABA block copolymer in water. Macromolecules 1987; 20: 3089-3091.
33. Zhou Z, Chu B. Light-scattering study on the association behavior of triblock polymers of ethylene oxide and propylene oxide in aqueous solution. J Colloid Interface Sci 1988; 126: 171-180.
34. Wanka G, Hoffman H, Ulbricht W. The aggregation behavior of poly-(oxyethylene)-poly-(oxypropylene)-poly-(oxyethylene)-block-copolymers in aqueous solution. Colloid Polym. Sci 1990; 268: 101-117.
35. Mortensen K. Block copolymer in aqueous solution: Micelle formation and hard-sphere crystallization. Progr Colloid Polym Sci 1993; 93: 72-75.
36. Schillén K, Glatter O, Brown W. Characterization of a PEO-PPO-PEO block copolymer system, Progr. Colloid Polym. Sci. 93 (1993) 66-71.
37. Bohorquez M, Koch C, Trygstad T, Pandit N. A study of the temperature-dependent micellization of pluronic F127. J Colloid Interface Sci. 1999; 216: 34-40.
38. Cabana A, Ait-Kadi A, Juhasz J. Study of the gelation process of polyethylene oxidepolypropylene oxide-polyethylene oxide copolymer (poloxamer 407) aqueous solutions. J Colloid Interface Sci 1997; 190: 307-312.
39. Mortensen K, Pederson JS. Structural study on the micelle formation of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer in aqueous solution. Macromolecules 1993; 26: 805-812.
40. Cao Y, Rodriguez A, Vacanti M, Ibarra C, Arevalo C, Vacanti CA. Comparative study of the use of poly(glycolic acid), calcium alginate and pluronics in the engineering of autologous porcine cartilage. J Biomater Sci Polym Ed 1998; 9: 475-487.
41. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 1999; 184: 189-198.
42. Saim AB, Cao Y, Weng Y, Chang CN, Vacanti MA, Vacanti CA, Eavey RD. Engineering autogenous cartilage in the shape of a helix using an injectable hydrogel scaffold. Laryngoscope 2000; 10: 1694-1697.
43. Scherlund M, Brodin A, Malmsten M. Micellization and gelation in block copolymer systems containing local anesthetics. Int J Pharm 2000; 211: 37-49.
44. Dumortier G, Groissord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23: 2709-2728.
45. Gong CY, Shi S, Dong PW, Yang B, Qi XR, Guo G, Gu YC, Zhao X, Wei YQ, Qian ZY. Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive PCL-PEG-PCL hydrogel. Part I. Synthesis, characterization, and acute toxicity evaluation. J Pharm Sci 2009; 98: 4684-4694.
46. Reeve L. The poloxamers: their chemistry and medical applications. In: Domb A, Kost Y, Wiseman D, editors. Handbook of Biodegradble Polymers, Drug Targeting and Delivery, vol. 7, London, Great Britain: Harwood Academic Publishers; 1997; pp 231-249.
47. Chen CC, Fang CL, Al-Suwayeh SA, Leu YL, Fang JY. Transdermal delivery of selegiline from alginate-Pluronic composite thermogels. Int J Pharm 2011; 415: 119-128.
48. Moebus K, Siepmann J, Bodmeier R. Alginate-poloxamer microparticles for controlled drug delivery to mucosal tissue. Eur J Pharm Biopharm 2009; 72: 42-53.
49. Alexandridis P, Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block-copolymer surfactants in aqueoussolutions and at interfaces-thermodynamics, structure, dynamics, and modeling. Colloid Surf A Physicochem Eng Aspects 1995; 96: 1-46.
50. Xiong XY, Tam KC, Gan LH. Polymeric nanostructures for drug delivery applications based on Pluronic copolymer systems. J Nanosci Nanotechnol 2006; 6: 2638-2650.
51. Hsu SH, Leu YL, Hu JW, Fang JY. Physicochemical characterization and drug release of thermosensitive hydrogels composed of a hyaluronic acid/Pluronic F127 graft. Chem Pharm Bull 2009; 57: 453-458.
52. Kim JH, Choi HK. Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. Int J Pharm 2002; 236: 81-85.
53. Vitória M, Bentley LB, Marchetti JM, Ricardo N, Ali-Abi Z, Collett JH. Influence of lecithin on some physical chemical properties of poloxamer gels: rheological, microscopic and in vitro permeation studies. Int J Pharm 1999; 193: 49-55.
54. Muzzalupo R, Tavano L, Cassano R, Trombino S, Ferrarelli T, Picci N. A new approach for the evaluation of niosomes as effective transdermal drug delivery systems. Eur J Pharm Biopharm 2011; 79: 28-35.
55. Sharma V, Stebe K, Murphy JC, Tung L. Poloxamer 188 decreases susceptibility of artificial lipid membranes to electroporation. Biophysical J 1996; 71: 3229-3241.
56. Grüning N, Müller-Goymann CC. Physicochemical characterisation of a novel thermogelling formulation for percutaneous penetration of 5-aminolevulinic acid. J Pharm Sci 2008; 97: 2311-2323.
57. van Hemelrijck C, Müller-Goymann CC. Characterization of a pseudo ternary phase diagram of poloxamer 407 systems for potential application of 5-aminolevulinic acid in photodynamic therapy. Int J Pharm 2011; 420: 297-303.